Variable | LRR-free (Number = 800) | LRR (Number = 19) | HR (95%CI) | P-value |
---|---|---|---|---|
Age at diagnosis | ||||
> 50 | 522 | 7 | reference | |
< 50 | 278 | 12 | 3.22 (1.28 to 8.33) | 0.01 |
T stage | ||||
T1 | 604 | 9 | reference | |
T2 | 187 | 8 | 2.95 (1.14-7.64) | 0.03 |
T3 | 9 | 2 | 19.8 (4.24-92.3) | < 0.01 |
Pathologic stage | ||||
I | 450 | 4 | Reference | |
IIA and IIB | 335 | 11 | 3.74 (1.19-11.7) | 0.02 |
IIIA, IIIB, IIIC and IV | 15 | 4 | 31.8 (7.94- 127) | < 0.01 |
Number of positive lymph nodes | ||||
0 | 579 | 7 | reference | |
1-3 | 209 | 10 | 3.94 (1.50-10.3) | 0.01 |
> 4 | 8 | 2 | 23.3 (4.83- 112) | < 0.01 |
Modified Black's nuclear grade | ||||
3 versus 1,2 | 6.93 (2.30-20.88) | < 0.01 | ||
ER or PR | ||||
Negative | 137 | 11 | reference | |
Positive | 648 | 8 | 0.15 (0.06-0.38) | < 0.01 |
HER2+ | ||||
Negative | 653 | 15 | reference | |
Positive | 105 | 4 | 1.64 (0.54-4.94) | 0.38 |
Lymphovascular invasion | ||||
Negative | 555 | 9 | reference | |
Positive | 127 | 10 | 5.08 (2.06-12.5) | < 0.01 |
Received trastuzumab (in HER2+ patients) | ||||
No | 78 | 2 | reference | |
Yes | 26 | 2 | 3.87 (0.53-28.1) | 0.18 |
Systemic therapy | ||||
No | 141 | 3 | reference | |
Yes | 658 | 16 | 1.11 (0.32-3.80) | 0.87 |
Constructed Subtype | ||||
HR+/HER2- | 569 | 5 | reference | |
HR+/HER2+ | 54 | 3 | 6.25 (1.49-26.2) | 0.01 |
HR-/HER2+ | 50 | 1 | 2.24 (0.26-19.2) | 0.46 |
HR-/HER2- | 84 | 10 | 13.6 (4.63-39.7) | < 0.01 |